Your browser doesn't support javascript.
loading
Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A post hoc analysis of the randomized FLOWER-MI trial.
Tea, Victoria; Morelle, Jean-François; Gallet, Romain; Cayla, Guillaume; Lemesle, Gilles; Lhermusier, Thibault; Dillinger, Jean-Guillaume; Ducrocq, Grégory; Angouvant, Denis; Cottin, Yves; Chamandi, Chekrallah; le Bras, Alicia; Steg, Philippe Gabriel; Montalescot, Gilles; Nelson, Anaïs Charles; Simon, Tabassome; Chatellier, Gilles; Danchin, Nicolas; Puymirat, Etienne.
Afiliação
  • Tea V; Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France; Université de Paris, 75006 Paris, France.
  • Morelle JF; Clinique St. Martin, 14000 Caen, France.
  • Gallet R; Service de cardiologie, Hôpitaux Universitaires Henri Mondor, AP-HP, 94000 Créteil, France; U955-IMRB, Equipe 03, Inserm, Université Paris Est Creteil (UPEC), Ecole Nationale Vétérinaire D'Alfort (EnVA), 94700 Maisons-Alfort, France.
  • Cayla G; Centre Hospitalier Universitaire de Nîmes, 30900 Nîmes, France; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France.
  • Lemesle G; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Cardiac Intensive Care Unit, CHU de Lille, 59000 Lille, France; Heart and Lung Institute, CHU de Lille, Institut Pasteur of Lille, Inserm U1011, 59000 Lille, France.
  • Lhermusier T; Department of Cardiology, Intensive Cardiac Care Unit, Rangueil University Hospital, 31059 Toulouse, France; Medical School, Toulouse III Paul Sabatier University, 31059 Toulouse, France.
  • Dillinger JG; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Department of Cardiology, Hôpital Lariboisière, AP-HP, Inserm U-942, Université de Paris, 75010 Paris, France.
  • Ducrocq G; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Department of Cardiology, Hôpital Bichat, AP-HP, 75018 Paris, France; Inserm U1148, Laboratory for Vascular Translational Science, 75018 Paris, France; Université de Paris, 75005 Paris, France.
  • Angouvant D; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Cardiology Department, University Hospital of Tours, 37000 Tours, France.
  • Cottin Y; PEC2, EA 7460, University of Bourgogne Franche-Comté, 21000 Dijon, France; Cardiology Department, University Hospital Centre of Dijon Bourgogne, 21000 Dijon, France.
  • Chamandi C; Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France; Université de Paris, 75006 Paris, France.
  • le Bras A; Clinical Research Unit Eco Île de France, Hôpital Hôtel Dieu, AP-HP, 75004 Paris, France.
  • Steg PG; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Department of Cardiology, Hôpital Bichat, AP-HP, 75018 Paris, France; Inserm U1148, Laboratory for Vascular Translational Science, 75018 Paris, France; Université de Paris, 75005 Paris, France.
  • Montalescot G; Sorbonne Université, ACTION Study Group, Institut de Cardiologie (AP-HP), Inserm UMRS 1166, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
  • Nelson AC; Clinical Research Unit and CIC 1418 Inserm, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
  • Simon T; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Department of Clinical Pharmacology and Unité de Recherche Clinique (URCEST), Hôpital Saint Antoine, AP-HP, 75012 Paris, France; Université Pierre et Marie Curie (UPMC-Paris 06), 75005 Paris, France; Inserm U-698, 75012 Paris, Fr
  • Chatellier G; Clinical Research Unit and CIC 1418 Inserm, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France.
  • Danchin N; Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Université de Paris, 75006 Paris, France.
  • Puymirat E; Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France; French Alliance for Cardiovascular Trials (FACT), 75018 Paris, France; Université de Paris, 75006 Paris, France. Electronic address: etienne.puymirat@aphp.fr.
Arch Cardiovasc Dis ; 115(10): 496-504, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36096979
ABSTRACT

BACKGROUND:

In patients with ST-segment elevation myocardial infarction and multivessel disease, percutaneous coronary intervention for non-culprit lesions is superior to treatment of the culprit lesion alone. The optimal timing for non-infarct-related artery revascularization - immediate versus staged - has not been investigated adequately.

AIM:

We aimed to assess clinical outcomes at 1 year in patients with ST-segment elevation myocardial infarction with multivessel disease using immediate versus staged non-infarct-related artery revascularization.

METHODS:

Outcomes were analysed in patients from the randomized FLOWER-MI trial, in whom, after successful primary percutaneous coronary intervention, non-culprit lesions were assessed using fractional flow reserve or angiography during the index procedure or during a staged procedure during the initial hospital stay, ≤5 days after the index procedure. The primary outcome was a composite of all-cause death, non-fatal myocardial infarction and unplanned hospitalization with urgent revascularization at 1year.

RESULTS:

Among 1171 patients enrolled in this study, 1119 (96.2%) had complete revascularization performed during a staged procedure, and 44 (3.8%) at the time of primary percutaneous coronary intervention. During follow-up, a primary outcome event occurred in one of the patients (2.3%) with an immediate strategy and in 55 patients (4.9%) with a staged strategy (adjusted hazard ratio 1.44, 95% confidence interval 0.39-12.69; P=0.64).

CONCLUSIONS:

Staged non-infarct-related artery complete revascularization was the strategy preferred by investigators in practice in patients with ST-segment elevation myocardial infarction with multivessel disease. This strategy was not superior to immediate revascularization, which, in the context of this trial, was used in a small proportion of patients. Further randomized studies are needed to confirm these observational findings.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infarto do Miocárdio com Supradesnível do Segmento ST / Revascularização Miocárdica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infarto do Miocárdio com Supradesnível do Segmento ST / Revascularização Miocárdica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article